Wisconsin is currently home to 1262 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Aurora St Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Myocarditis Acute, Cancer
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin
Conditions: Lower Respiratory Tract Illness
Register for Updates
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients with Brain Tumors
NCT05023434
Recruiting
The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as possible without a resultant permanent neurological deficit. However, the subjective nature of current intraoperative hand motor assessments do not offer a comprehensive understanding of how hand strength and function may be impacted by resection. Additionally,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Brain Tumor, Brain Cancer, Motor Cortex; Lesion
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Uterine Serous Carcinoma
Register for Updates
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT04683315
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT03322995
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867
Recruiting
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hepatocellular Carcinoma, Gastric Cancer
Register for Updates
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Register for Updates
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: * To enhance the understanding of the variability, progression, and natural history of F... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin
Conditions: Fabry Disease
Register for Updates
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
NCT06494072
Recruiting
The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia. The main questions it aims to answer are: * Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children? * Does a 5 da... Read More
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
11/18/2024
Locations: Childrens Wisconsin, Milwaukee, Wisconsin
Conditions: Community Acquired Pneumonia in Children
Register for Updates
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110
Recruiting
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Non Hodgkin Lymphoma
Register for Updates